Summary The prognostic role of the epidermal growth factor receptor (EGFR) and the related receptor p185HER-2 in lung cancer is as yet undefined. We investigated the immunohistochemical expression of EGFR (monoclonal antibody RI; Amersham) and pl85HER-2 (polyclonal antibody A485; Dako) in cryosections. A total of 186 unselected and systemically untreated patients with non-small-cell lung cancer (NSCLC) diagnosed and treated at Odense University Hospital, Denmark, were included. Median follow-up period was 66 months.
The improvement in survival for most cancer patients has only been modest and lung cancer is no exception to this rule. Surgical resection alone offers a chance of cure in early-stage non-small-cell lung cancer (NSCLC) (Mountain, 1994) . However, some clinical trials indicate possible benefit from adjuvant (Souquet et al., 1993) or neoadjuvant chemotherapy (Rosell et al., 1994; Roth et al., 1994) . A prerequisite for further substantiation of these observations is, however, a proper prognostic classification of these patients. A whole cascade of tumour-biological characteristics related to growth, invasion and metastatic potential has been suggested for their possible prognostic value (Gazdar, 1994; Richardson and Johnson, 1993) . The main criticisms of most prognostic studies are small sample size, non-homogeneous populations owing to selection bias and use of optimal cut-off values for prognostic variables without a prestated hypothesis Simon and Altman, 1994) . In addition, various techniques have been employed without proper methodological validation. Not surprisingly, conflicting results have been obtained and it is still not possible to conclude which factors give valid prognostic information.
The protein product of the oncogene HER-1, the epidermal growth factor receptor (EGFR), is a 170 kilodalton (kDa) transmembrane protein, exhibiting an extracellular ligand-binding area, a transmembrane domain and an intracellular region with tyrosine kinase activity. The receptor is able to activate cytoplasmic signal proteins that trigger DNA synthesis associated with proliferation and differentiation (Prigent and Lemoine, 1992) .
It has recently been shown that the HER-2 (or c-erbB-2)
proto-oncogene encodes a 185 kDa glycoprotein (pl85HER-2), which has molecular homology with EGFR. Like EGFR, the p185HER-2 is a transmembrane receptor with tyrosine kinase activity (Prigent and Lemoine, 1992) . The type 1 (EGFR-related) family of growth factor receptors is important in the regulation of normal cells and in the carcinogenic process (Prigent and Lemoine, 1992) , but whether expression of these receptors reflects prognosis remains to be established.
To determine whether immunohistochemical detection of EGFR and/or pl85HER-2 in frozen tissue is of prognostic importance in patients with NSCLC, we conducted the present hypothesis-generating study in a homogeneously treated and unselected cohort of 186 patients. With the exception of two patients, cytotoxic therapy had not been given during the course of the disease.
Materials and methods
Patients and tumour samples A total of 186 patients with NSCLC were followed for a median of 66 (40-119) months. The 131 men and 55 women had a median age of 61 (42-79) years at the time of diagnosis. Characteristics of patients were collected from their records (Table I) .
All the patients were treated surgically at the Department of Thoracic Surgery at Odense University Hospital, Denmark, from 1984 to 1991. Pulmonary resection was accompanied by intraoperative evaluation of tumour extension with biopsy of suspicious areas and lymph nodes; complete mediastinal lymph node dissection or systematic lymph node sampling was not performed. The stage of the primary tumour (Table I) We found no correlation between EGFR staining and survival in patients with squamous cell carcinoma (relative risk 1.14; 95% I 0.79-1.66), adenocarcinoma of the lung, stage I and/or II, or in the entire group of patients with NSCLC ( Figure 1) . This was confirmed, whether we applied the cut-off points used in Follow-up time (years) Figure 2 The survival of 186 patients with NSCLC categorised according to pl85HER-2 content (P= 0.9). ----, None (n = 29); , low (n= 108); ---, high (n=49).
status was also related to histology (Table III) , but in contrast to EGFR, the level of p185HER-2 staining was lower in squamous cell carcinomas than in adenocarcinomas and large cell carcinomas (K-W; P<0.001). p185HER-2 content was not correlated with age, tumour size, lymph node involvement, stage or histological grading. We found no correlation between p185HER-2 staining and survival in patients with squamous cell carcinoma, adenocarcinoma of the lung (relative risk 0.89; 95% CI 0.56-1.41), stage I and/or II, nor in the entire group of patients with NSCLC ( Figure 2 ). This was confirmed, whether we applied the cut-off points for p185HER-2 from Table III (three groups), used median values (two groups), used quartiles (four groups) or related survival to intensity of staining.
In vitro studies (Kokai et al., 1989) suggested that simultaneous overexpression of both EGFR and p185HER-2 acts synergistically. Consequently, we investigated whether patients with EGFR-positive and p185HER-2_positive tumours might have a poorer prognosis than patients with overexpression of either of the receptors or no overexpression at all. To analyse groups of comparable size we used the median value as cut-off point for both receptors. As for the individual receptor, overexpression of both receptors was of no prognostic significance (P=0.3; Figure 3 ).
Discussion
A detailed knowledge of prognostic and predictive factors can be essential for predicting patients' outcome and for proper selection of treatment, but also for optimal trial design and for comparison of results. New prognostic factors Follow-up time (years) Figure 3 The survival of 186 patients with NSCLC categorised according to EGFR and pl85HER-2 content (P=0.38). ----, high EGFR and high p185HER-2 (n = 50); , high EGFR or high p185HER-2 (n = 103); ---, low EGFR and low pl85HER-2 (n =33). markers truly independent prognostic factors? Numerous studies investigating different factors, different cut-off points, different subsets of patients, and different end points are performed, often even without a prespecified hypotheses (Simon and Altman, 1994) Simon and Altman (1994) have proposed a number of meaningful guidelines that should be fulfilled before definite statements are made concerning the prognostic significance of, for example, the EGF receptor family. In this regard, breast cancers are probably the best studied group of malignant tumours, with several large well-conducted studies which meet most of these guidelines; the majority of large well-conducted studies of breast cancer have found that overexpression of the EGF receptor family is associated with poor prognosis in patients with node-positive breast cancer although results on node-negative patients remain contradictory. This difference may be caused by a treatment effect, i.e. EGFR or pl85HER-2 are predictive but not prognostic factors (Knoop et al., 1994; Ravdin and Chamness, 1995 (Prigent and Lemoine, 1992) . These receptors are important in the regulation of normal cell growth, they are connected to the carcinogenic process and they are potential prognostic factors in a variety of human malignant tumours (Gullick, 1991; Prigent and Lemoine, 1992) . (Veale et al., 1987; Hendler and Ozanne. 1984 : Sobol et al.. 1987 : Kaseda et al., 1989 Berger et al.. 1987) and no correlation between EGFR and the size of the primarv tumour, lymph node status or stage (Kaseda et al.. 1989 : Dittadi et al., 1991 Veale et al.. 1989; Di Carlo et al., 1993; Bolufer et al.. 1993; Rusch et al.. 1993 : Dazzi et al., 1989 Volm and Mattern. 1993) .
However, when expression of EGFR or p185HER-2 has been correlated with outcome, conflicting results are presented. In some studies. overexpression of EGFR has been an indicator of bad prognosis (Volm et al., 1992 Hendler and Ozanne, 1984: Veale et al.. 1987) : in some studies expression of EGFR had no impact on outcome (Gorgoulis et al., 1992 : Scagliotti et al.. 1993 Rusch et al., 1993) . whereas still others indicated that patients with EGFR-positive tumours may survive longer than patients without EGFR expression (Dazzi et al.. 1989 : Veale et al.. 1993 .
The first immnunohistochemical studies to investigate the content of EGFR in patients with NSCLC were based on cryosections (Cerny et al.. 1986; Berger et al.. 1987 : Veale et al., 1987 : Sobol et al.. 1987 . However, almost all subsequent studies used paraffin-embedded tissues. Table IV summarises published immunohistochemical studies that correlate EGFR with outcome in NSCLC. Three studies (Dazzi et al.. 1989; Tateishi et al.. 1990; Rusch et al., 1993) failed to find a correlation between EGFR expression and prognosis. whereas three other studies, which included patients with squamous cell carcinoma. showed that a high EGFR content was correlated with poor prognosis. However, these three studies. which were all published by Volm et al. (Volm et al.. 1992 . 1993 : Volm and Mattern, 1993 , do not state how patients were selected, and these different studies might at least partly include the same patients.
The oncogene HER-2 and its gene product pl85HER-2 have also been studied in NSCLC. In accordance with most studies.
we found that pl85HER, staining was more prominent in adenocarcinomas than in squamous cell carcinomas and large cell carcinoma (Kern et al., 1990; Tateishi et al., 1991; Shi et al.. 1992 ). In agreement with most studies, we also found no relationship between p I85HER-2 and the extension of the disease (Volm et al.. 1992 . 1993 : Shi et al., 1992 Bongiorno et al.. 1994) . Most authors agree that p185 IR-' staining is not correlated with prognosis in patients with squamous cell carcinoma (Kern et al.. 1990 : Volm et al.. 1992 . 1993 : Tateishi et al.. 1991 . However, a higher content of pl85HER-is correlated with a diagnosis of adenocarcinoma of the lung. and p185HER-' may be a prognostic factor in these adenocarcinomas (Kern et al.. 1990 : Tateishi et al.. 1991 . (Kern et al., 1990) . In a later study, Kern et al. (1994) evaluated the prognostic significance of pl85HER-2 expression and ras gene mutations in 46 patients with pulmonary adenocarcinoma. By univariate and multivariate analysis they showed that p185HER-' expression was associated with shortened survival. whereas K-ras mutation approached significance as a poor prognostic indicator. The impact of both p185 IR-2 expression and a K-ras mutation on survival was additive and highly significant. However. these 46 patients with adenocarcinomas were operated on during the same period as the 29 patients previously mentioned (Kern et al.. 1990) 
